Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study

References

• Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam – burden and control efforts: a narrative scoping review. Cancer Control. 2019;26(1):1073274819863802. doi:10.1177/1073274819863802
   Web of Science ®Google Scholar
• Van Thuan T, Anh PT, Van Tu D. Cancer control in Vietnam: where are we? Cancer Control. 2016;99. Available from http://www.cancercontrol.info/cc2016/cancer-control-in-vietnam-where-we-are/.
   Google Scholar
• Nakajima T, Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology. 1989;36(2):79–85.
   PubMedGoogle Scholar
• Jung JJ, Cho JH, Shin S, Shim YM. Surgical treatment of anastomotic recurrence after gastrectomy for gastric cancer. Korean J Thorac Cardiovasc Surg. 2014;47(3):269–274. doi:10.5090/kjtcs.2014.47.3.269
   PubMedGoogle Scholar
• Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. doi:10.1002/14651858.CD004064.pub4
   PubMed Web of Science ®Google Scholar
• Li B, Chen L, Luo HL, Yi FM, Wei YP, Zhang WX. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: a systematic review and meta-analysis. World J Clin Cases. 2019;7(5):600–615. doi:10.12998/wjcc.v7.i5.600
   PubMed Web of Science ®Google Scholar
• Kilickap S, Yalcin S, Ates O, Tekuzman G. The first line systemic chemotherapy in metastatic gastric carcinoma: a comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting. Hepatogastroenterology. 2011;58(105):208–212.
   PubMedGoogle Scholar
• Babu KG, Chaudhuri T, Lakshmaiah KC, et al. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: a prospective Phase II study from South India. Indian J Cancer. 2017;54(1):47–51. doi:10.4103/ijc.IJC_168_17
   PubMed Web of Science ®Google Scholar
• Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25(22):3217–3223. doi:10.1200/JCO.2006.08.0135
   PubMed Web of Science ®Google Scholar
• Teker F, Yilmaz B, Kemal Y, Kut E, Yucel I. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey. Asian Pac J Cancer Prev. 2014;15(16):6727–6732. doi:10.7314/APJCP.2014.15.16.6727
   PubMedGoogle Scholar
• Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol. 2015;33(33):3874–3879. doi:10.1200/JCO.2015.60.7465
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–4997. doi:10.1200/JCO.2006.06.8429
   PubMed Web of Science ®Google Scholar
• Chen XL, Chen XZ, Yang C, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(4):e60320. doi:10.1371/journal.pone.0060320
   PubMed Web of Science ®Google Scholar
• Wang J, Xu R, Li J, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19(1):234–244. doi:10.1007/s10120-015-0457-4
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Cummins MM, Sourjina T, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102(3):475–481. doi:10.1038/sj.bjc.6605522
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. JCO. 2005;23(24):5542–5551. doi:10.1200/JCO.2005.02.027
   PubMed Web of Science ®Google Scholar
• Park SH, Lee WK, Chung M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17(2):225–229. doi:10.1097/00001813-200602000-00015
   PubMed Web of Science ®Google Scholar
• Chon HJ, Rha SY, Im CK, et al. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 2009;41(4):196–204. doi:10.4143/crt.2009.41.4.196
   PubMed Web of Science ®Google Scholar
• Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2007;57(3):348–358. doi:10.1016/j.lungcan.2007.03.014
   PubMed Web of Science ®Google Scholar
• du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320–1329. doi:10.1093/jnci/djg036
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194–3200. doi:10.1200/JCO.2003.02.153
   PubMed Web of Science ®Google Scholar
• Chintala L, Vaka S, Baranda J, Williamson SK. Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now? Oncol Rev. 2011;5(2):129–140. doi:10.4081/oncol.2011.129
   Google Scholar
• Ruoff CA, Hong B, Kaplan BH, Pollack S. Single-center experience with paclitaxel (T), carboplatin (C), and capecitabine (X) in the treatment of advanced esophagogastric cancer. JCO. 2013;31(4_suppl):116. doi:10.1200/jco.2013.31.4_suppl.116
   Web of Science ®Google Scholar
• Hosein PJ, Ray N, Anthony LB, et al. Paclitaxel, carboplatin, and capecitabine (TCX) with and without radiation in locally advanced and metastatic distal esophageal and esophagogastric junction cancer: a single-center retrospective review. JCO. 2015;33(3_suppl):197. doi:10.1200/jco.2015.33.3_suppl.197
   Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). 2009:79.
   Google Scholar
• Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–673. doi:10.1093/annonc/mdn717
   PubMed Web of Science ®Google Scholar
• Seo BG, Oh SY, Lee DM, et al. A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer. Cancer Res Treat. 2007;39(1):6–9. doi:10.4143/crt.2007.39.1.6
   PubMedGoogle Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. doi:10.1056/NEJMoa073149
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–267. doi:10.1200/JCO.1997.15.1.261
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–1442. doi:10.1200/JCO.2007.13.9378
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450–1457. doi:10.1093/annonc/mdn166
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–192.
   PubMed Web of Science ®Google Scholar
• Sternberg C, Kelsen D, Dukeman M, Leichman L, Carboplatin: HR. A new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep. 1985;69(11):1305–1307.
   PubMedGoogle Scholar
• Queisser W, Preusser P, Mross KB, et al. Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of phase I/II study group of the Association for Medical. Oncology of the German Cancer Society. Oncol Res Treat. 1990;13:190–193.
   Google Scholar
• Mannell A, Winters Z. Carboplatin in the treatment of esophageal cancer. S Afr Med J. 1989;76(5):213–214.
   PubMed Web of Science ®Google Scholar
• Polyzos A, Felekouras E, Karatzas T, et al. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer: a phase II study. Anticancer Res. 2012;32(9):4151–4156.
   PubMed Web of Science ®Google Scholar
• Bilici A, Selcukbiricik F, Demir N, Oven Ustaalioglu BB, Dikilitas M, Yildiz O. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Asian Pac J Cancer Prev. 2014;15(20):8661–8666. doi:10.7314/APJCP.2014.15.20.8661
   PubMedGoogle Scholar
• Dong L, Li J, Lou XP, et al. Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. J Int Med Res. 2014;42(3):737–743. doi:10.1177/0300060513510657
   PubMed Web of Science ®Google Scholar
• Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer. 2006;6(1):274. doi:10.1186/1471-2407-6-274
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol. 2005;23(3):494–501. doi:10.1200/JCO.2005.02.163
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol. 2007;25(22):3205–3209. doi:10.1200/JCO.2006.10.4968
   PubMed Web of Science ®Google Scholar
• Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3–4):643–671. doi:10.1007/s10555-013-9444-6
   PubMed Web of Science ®Google Scholar
• Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem. 2008;283(23):15647–15655. doi:10.1074/jbc.M800543200
   PubMed Web of Science ®Google Scholar
• Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng. 2009;11(1):177–202. doi:10.1146/annurev-bioeng-061008-124949
   PubMed Web of Science ®Google Scholar
• Thomas SN, Tong Z, Stebe KJ, Konstantopoulos K. Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology. 2009;46(3):207–225. doi:10.3233/BIR-2009-0534
   PubMed Web of Science ®Google Scholar
• Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327–334. doi:10.1016/0092-8674(89)90970-7
   PubMed Web of Science ®Google Scholar
• Cai Q, Zhou W, Li J, et al. Association of preoperative serum carcinoembryonic antigen and gastric cancer recurrence: a large cohort study. J Cancer. 2021;12(2):397–403. doi:10.7150/jca.47899
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TNT. T Cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–562. doi:10.1016/j.ccell.2018.03.012
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458–469. doi:10.1038/s41423-018-0004-4
   PubMed Web of Science ®Google Scholar
• Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–691. doi:10.1016/j.cell.2016.11.037
   PubMed Web of Science ®Google Scholar
• Deng K, Yang L, Hu B, Wu H, Zhu H, Tang C. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One. 2015;10(4):e0124151. doi:10.1371/journal.pone.0124151
   PubMed Web of Science ®Google Scholar
• Ma T, Wu Z, Zhang X, et al. Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma. BMC Cancer. 2021;21(1):1326. doi:10.1186/s12885-021-09079-7
   PubMed Web of Science ®Google Scholar
• Nakajima K, Ochiai T, Suzuki T, et al. Impact of preoperative serum carcinoembryonic antigen, CA 19-9 and alpha fetoprotein levels in gastric cancer patients. Tumour Biol. 1998;19(6):464–469. doi:10.1159/000030038
   PubMedGoogle Scholar
• Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008;25(10):1075–1084. doi:10.1007/s12325-008-0100-4
   PubMed Web of Science ®Google Scholar
• Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76(4):266–271. doi:10.1002/jso.1044
   PubMed Web of Science ®Google Scholar
• Gaspar MJ, Arribas I, Coca MC, Díez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001;22(5):318–322. doi:10.1159/000050633
   PubMedGoogle Scholar
• Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16(3–4):105–110. doi:10.1155/2000/595492
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia: diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203–212. doi:10.1002/ajh.23628
   PubMed Web of Science ®Google Scholar
• Kang YK, Ryu MH, Yoo C, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2011;67(6):1435–1443. doi:10.1007/s00280-010-1444-4
   PubMed Web of Science ®Google Scholar